推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 11月23日，國家衛(wèi)生計生委副主任、國家中醫(yī)藥管理局局長王國強在首屆中醫(yī)科學大會上指出，要善于把中醫(yī)藥的經(jīng)濟資源優(yōu)勢轉(zhuǎn)化為產(chǎn)業(yè)優(yōu)勢，加快中醫(yī)藥健康服務發(fā)展，為經(jīng)濟增長增添新的動力。
王國強說，中醫(yī)藥是潛力巨大的經(jīng)濟資源，利用好這一資源，是推動經(jīng)濟發(fā)展方式轉(zhuǎn)變的重要抓手。中醫(yī)藥涉及產(chǎn)業(yè)鏈條長，吸納從業(yè)人員多，拉動消費作用大，在促進就業(yè)、擴大內(nèi)需方面有很大潛力，相關(guān)產(chǎn)品和服務出口也具有廣闊空間。2013年，國務院出臺了關(guān)于促進健康服務業(yè)發(fā)展的若干意見，明確提出要全面發(fā)展中醫(yī)藥醫(yī)療保健服務。
他表示，當前和今后一個時期，推動中醫(yī)藥健康產(chǎn)業(yè)成為我國最具競爭力的戰(zhàn)略性新興產(chǎn)業(yè)之一。強化中藥產(chǎn)業(yè)發(fā)展規(guī)劃統(tǒng)籌，開展第四次全國中藥資源普查，加強中藥資源保護、開發(fā)和合理利用研究，發(fā)展道地藥材，支持醫(yī)療機構(gòu)研制應用特色中藥制劑。落實好中醫(yī)藥健康服務發(fā)展規(guī)劃，加快中醫(yī)藥養(yǎng)生保健、醫(yī)療康復服務以及健康文化、健康養(yǎng)老、健康旅游等服務發(fā)展，推動中醫(yī)藥健康產(chǎn)品研發(fā)。
